{"id":"NCT01996839","sponsor":"Bausch & Lomb Incorporated","briefTitle":"Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","officialTitle":"Loteprednol Etabonate Ophthalmic Gel, 0.38% (BID and TID) Versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12","primaryCompletion":"2014-05","completion":"2014-07","firstPosted":"2013-11-27","resultsPosted":"2020-09-03","lastUpdate":"2020-09-25"},"enrollment":514,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Inflammation","Pain","Cataract"],"interventions":[{"type":"DRUG","name":"Loteprednol Etabonate Gel (BID)","otherNames":["Lotemax"]},{"type":"DRUG","name":"Loteprednol Etabonate Gel (TID)","otherNames":["Lotemax"]},{"type":"DRUG","name":"Vehicle (BID)","otherNames":["Vehicle"]},{"type":"DRUG","name":"Vehicle (TID)","otherNames":["Vehicle"]}],"arms":[{"label":"Loteprednol Etabonate Gel (BID)","type":"EXPERIMENTAL"},{"label":"Vehicle (BID)","type":"ACTIVE_COMPARATOR"},{"label":"Loteprednol Etabonate Gel (TID)","type":"EXPERIMENTAL"},{"label":"Vehicle (TID)","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate ophthalmic gel","primaryOutcome":{"measure":"Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells","timeFrame":"8 days","effectByArm":[{"arm":"Vehicle (BID and TID)","deltaMin":16,"sd":null},{"arm":"Loteprednol Etabonate Gel (BID)","deltaMin":46,"sd":null},{"arm":"Loteprednol Etabonate Gel (TID)","deltaMin":49,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":172},"commonTop":[]}}